Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr 28:7:125-36.
doi: 10.2147/HIV.S50025. eCollection 2015.

Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review

James Wilton  1 , Heather Senn  2 , Malika Sharma  3 , Darrell Hs Tan  4
Affiliations
Review

Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review

James Wilton et al. HIV AIDS (Auckl). .

Abstract

Despite significant efforts, the rate of new HIV infections worldwide remains unacceptably high, highlighting the need for new HIV prevention strategies. HIV pre-exposure prophylaxis (PrEP) is a new approach that involves the ongoing use of antiretroviral medications by HIV-negative individuals to reduce the risk of HIV infection. The use of daily tenofovir/emtricitabine as oral PrEP was found to be effective in multiple placebo-controlled clinical trials and approved by the United States Food and Drug Administration. In addition, the Centers for Disease Control and Prevention in the United States and the World Health Organization have both released guidelines recommending the offer of oral PrEP to high-risk populations. The scale-up of PrEP is underway, but several implementation questions remain unanswered. Demonstration projects and open-label extensions of placebo-controlled trials are ongoing and hope to contribute to our understanding of PrEP use and delivery outside the randomized controlled trial setting. Evidence is beginning to emerge from these open-label studies and will be critical for guiding PrEP scale-up. Outside of such studies, PrEP uptake has been slow and several client- and provider-related barriers are limiting uptake. Maximizing the public health impact of PrEP will require rollout to be combined with interventions to promote uptake, support adherence, and prevent increases in risk behavior. Additional PrEP strategies are currently under investigation in placebo-controlled clinical trials and may be available in the future.

Keywords: HIV prevention; biomedical intervention; emtricitabine; tenofovir.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Truvadawhore T-shirt.
See this image and copyright information in PMC

References

    1. UNAIDS . The Gap Report. Geneva, Switzerland: UNAIDS; 2014. [Accessed December 23, 2014]. Available from: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_....
    1. Beyrer C, Baral SD, van Griensven F, et al. Global epidemiology of HIV infection in men who have sex with men. Lancet. 2012;380(9839):367–377. - PMC - PubMed
    1. El-Bassel N, Strathdee SA, El Sadr WM. HIV and people who use drugs in central Asia: confronting the perfect storm. Drug Alcohol Depend. 2013;132(Suppl 1):S2–S6. - PMC - PubMed
    1. US Public Health Service . Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2014: A Clinical Practice Guideline. Atlanta, GA: Centers for Disease Control and Prevention; 2014. [Accessed December 23, 2014]. Available from: http://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf.
    1. World Health Organization . Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations. Geneva, Switzerland: World Health Organization; 2014. [Accessed December 23, 2014]. Available from: http://apps.who.int/iris/bitstream/10665/128048/1/9789241507431_eng.pdf?....